Survival of 306 patients with therapy-related myeloid leukemia according to clinical and cytogenetic features: the University of Chicago series.4
| Clinical/cytogenetic subset . | No. of patients . | Median survival,mos (95% CI) . |
|---|---|---|
| Total group | 306 | 8 (7-9) |
| Presenting as t-MDS | 224 | 8.6 (7.6-9.9) |
| Presenting as t-AML | 82 | 6.9 (4.0-8.5) |
| Abnormal chromosome 5 | 63 | 7 |
| Abnormal chromosome 7 | 85 | 9 |
| Abnormalities of both chromosomes 5 and 7 | 66 | 5 |
| Recurring balanced rearrangement | 31 | 11 |
| Other clonal abnormality | 39 | 9 |
| Normal karyotype | 24 | 11 |
| Clinical/cytogenetic subset . | No. of patients . | Median survival,mos (95% CI) . |
|---|---|---|
| Total group | 306 | 8 (7-9) |
| Presenting as t-MDS | 224 | 8.6 (7.6-9.9) |
| Presenting as t-AML | 82 | 6.9 (4.0-8.5) |
| Abnormal chromosome 5 | 63 | 7 |
| Abnormal chromosome 7 | 85 | 9 |
| Abnormalities of both chromosomes 5 and 7 | 66 | 5 |
| Recurring balanced rearrangement | 31 | 11 |
| Other clonal abnormality | 39 | 9 |
| Normal karyotype | 24 | 11 |